Austrianova (the SG Austria group, Austrianova Singapore and Austrianova Thailand) is delighted to announce the appointment of Pierre Faddoul to the Austrianova management team as the company’s new Chief Financial Officer (CFO). Austrianova’s previous CFO, Louise Bussieres, will continue to be engaged in an advisory capacity.
Pierre, who is based in Singapore, received an MBA from ESSEC Business School (France) and a Masters in Economics from Universite Paris-II Assas (France). He formerly held positions with PWC as well as leading the investment research teams for Tokio Marine Asset Management and Deutsche Bank Asset & Wealth Management. He was also a former investment analyst with Aberdeen Asset Management and BNP Paribas Fortis.
“We are very pleased that Pierre Faddoul has joined Austrianova as our CFO. Pierre’s advice and support, working together with our previous CFO, Louise, has been invaluable over the last couple of years. The Company is continuing to ramp up its commercialization and growth phase, and having Pierre on board will support our activities significantly” stated Walter H. Gunzburg, Chairman of Austrianova.
Incoming CFO Pierre Faddoul said “I am honored to be taking on this position with Austrianova at this exciting stage of growth for the company. The multi-faceted opportunities that the company is currently facing further reinforces the wide appeal of its technology”.
“After more than 10 years of working as part of the Austrianova management team, I am happy to pass the baton on to Pierre but I shall continue to support Austrianova in every way possible in an advisory capacity” stated outgoing CFO, Louise Bussieres.
Austrianova (the SG Austria Group), is a biotech company with a global footprint and operations in Singapore and Thailand. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications as well as rebalancing the microbiome due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, enzymes, recombinant proteins, exosomes etc).
This release includes forward-looking statements regarding Austrianova (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the public offering, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors and the equity markets generally. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Austrianova undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.
Company and Technology Contact: email@example.com
For more information: http://www.austrianova.com